Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar

Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar

(MedPage Today) -- The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer. FDA granted the targeted agent an...

FDA approves Poherdy, first biosimilar of Perjeta, to treat HER-positive breast cancer

The FDA has approved Poherdy as the first interchangeable biosimilar to Perjeta, expanding treatment options for adults with HER2-positive breast cancer across both early-stage and metastatic settings.

Anti-HER2 Therapies: Biological Mechanisms and Toxicity Management - SPCC

Anti-HER2 Therapies: Biological Mechanisms and Toxicity Management - SPCC / cancer, OncoDaily, Oncology, Sharing Progress in Cancer Care, SPCC

FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The FDA approves pertuzumab-dpzb as the first interchangeable biosimilar for HER2-positive breast cancer, enhancing treatment options and accessibility.

FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications

The FDA approves Poherdy, a new biosimilar to Perjeta, enhancing treatment options for HER2+ breast cancer patients with affordability and efficacy.

FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer

The FDA approved Poherdy as the first interchangeable biosimilar to Perjeta for patients with HER2-positive breast cancer.